Therapeutic intervention with rapamycin/sirolimus, a mechanistic/mammalian target of rapamycin (mTOR) inhibitor, successfully decreases serum VEGF-D levels as well as stabilizes of pulmonary function in LAM patients12,13. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.